'Zombie Drug' in America's Streets: Lawmakers Demand Federal Action on Xylazine
A bipartisan coalition of 41 state attorneys general is pressing Congress to take decisive federal action against xylazine — a powerful veterinary tranquilizer that has quietly become one of the most dangerous adulterants in the U.S. illicit drug supply. In a letter sent to congressional leadership on March 31, 2026, the attorneys general called on lawmakers to pass the Combating Illicit Xylazine Act, a bill introduced in both the Senate (S.545) and the House (H.R.1266) in February 2025. The Senate Judiciary Committee ordered the bill to be reported favorably on March 26, 2026, a significant step forward for legislation that has been in the works for years.
Udumbara
.
A bipartisan coalition of 41 state attorneys general is pressing Congress to take decisive federal action against xylazine — a powerful veterinary tranquilizer that has quietly become one of the most dangerous adulterants in the U.S. illicit drug supply.
In a letter sent to congressional leadership on March 31, 2026, the attorneys general called on lawmakers to pass the Combating Illicit Xylazine Act, a bill introduced in both the Senate (S.545) and the House (H.R.1266) in February 2025. The Senate Judiciary Committee ordered the bill to be reported favorably on March 26, 2026, a significant step forward for legislation that has been in the works for years.
.
What Is Xylazine — and Why Is It So Dangerous?
Xylazine, commonly known by the street names "tranq" or "zombie drug," is a sedative approved for veterinary use in large animals such as horses and cattle. It is not approved for use in humans. Drug traffickers have increasingly used it as a low-cost additive to cut fentanyl and heroin.
The combination is particularly lethal. Because xylazine is not an opioid, it does not respond to overdose reversal agents such as naloxone (Narcan), reducing the effectiveness of traditional overdose interventions and increasing the danger when combined with opioids. In plain terms: when someone overdoses on a fentanyl-xylazine mix, the standard emergency treatment may not work.
Xylazine was initially concentrated in the Northeast, particularly Philadelphia, but has since spread across all four U.S. geographic regions. This expansion has been linked to a dramatic rise in xylazine-positive overdose deaths, with increases of over 1,100% in the South and 750% in the West.
The Legislation: What Would It Do?
The Combating Illicit Xylazine Act would list xylazine as a Schedule III controlled substance while protecting its legal use by veterinarians, farmers, and ranchers. Schedule III is the federal classification for substances with recognized medical use but significant potential for abuse — the same category as certain anabolic steroids and ketamine.
In addition to scheduling, the bill would require manufacturers and distributors to report inventory and sales to the DEA's tracking system, making it harder for xylazine to be diverted into the illicit market. It would also mandate reporting on the prevalence and risks of xylazine use.
Critically, lawmakers have been explicit that the bill will not burden farmers, ranchers, or veterinarians — who rely on xylazine to safely handle and treat large animals.
A Rare Show of Unity: Both Parties, All Regions
The breadth of support for the legislation is striking. Ninety national, state, and local organizations called on the Senate Judiciary Committee to advance the bill, including 18 major law enforcement organizations representing over one million officers, more than 70 organizations representing veterinary professionals and livestock producers, and two national coalitions of bereaved families. The Department of Justice, the Department of Health and Human Services, the DEA, and the Office of National Drug Control Policy have all voiced support.
The attorneys general coalition is co-led by Arkansas AG Tim Griffin, Connecticut AG William Tong, New York AG Letitia James, and Tennessee AG Jonathan Skrmetti — a mix of Republican and Democratic officials. Signatories come from more than 40 states and territories, including California, Texas, Ohio, Florida, and the District of Columbia.
"Illicit xylazine is costing lives in Connecticut and across the country," said AG Tong. "Congress must act now to make xylazine a controlled substance and give law enforcement the tools to stop its spread."
Chinese Supply Chains and Cartel Distribution
Officials have drawn a direct line between the xylazine crisis and foreign criminal networks. The source document notes that federal authorities have traced xylazine trafficking to Mexican cartels, with the raw chemical originating largely from China. Several China-based chemical companies have faced U.S. indictments and Treasury Department sanctions for allegedly facilitating the flow of xylazine and fentanyl precursors into American communities.
A Crisis in Context
Overall U.S. drug overdose deaths fell sharply in 2024, with CDC data estimating around 80,000 deaths — a decline of roughly 27% compared to 2023. While that is cause for cautious optimism, authorities warn that xylazine continues to complicate the picture, particularly because it is still not federally regulated.
Preliminary CDC data for the 12 months ending October 2025 projects around 71,500 overdose deaths — another decline of roughly 17%, though experts caution that the figures are still provisional.
What Comes Next
The Senate Judiciary Committee's vote to advance the bill represents the most concrete legislative progress on xylazine to date. The bill now moves toward a full Senate vote, with its House counterpart, led by Reps. Jimmy Panetta (D-Calif.) and August Pfluger (R-Texas), advancing in parallel.
The legislation has received strong bipartisan support in Congress, and the recent Senate Judiciary Committee advancement signals growing momentum. Whether that momentum translates into a final vote before year's end remains to be seen — but the pressure from 41 attorneys general across the country has made one thing clear: the states are no longer willing to wait.
.
Sources
- U.S. Senate Judiciary Committee – Bipartisan Support Statement: https://www.judiciary.senate.gov/press/rep/releases/bipartisan-combating-illicit-xylazine-act-receives-outpouring-of-support-ahead-of-judiciary-committee-vote
- Senator Cortez Masto – Bill Reintroduction Press Release: https://www.cortezmasto.senate.gov/news/press-releases/cortez-masto-grassley-reintroduce-bipartisan-legislation-to-crack-down-on-deadly-fentanyl-additive-xylazine/
- New Hampshire Department of Justice – Coalition Statement: https://www.doj.nh.gov/news-and-media/attorney-general-formella-bipartisan-coalition-urge-congress-pass-combating-illicit
- CDC – U.S. Drug Overdose Death Data (2024): https://www.cdc.gov/nchs/pressroom/releases/20250514.html
- CDC – Overdose Prevention Data Resources: https://www.cdc.gov/overdose-prevention/data-research/facts-stats/index.html
- PMC / SAGE Journals – "The Xylazine-Fentanyl Nexus: A Public Health Emergency": https://pmc.ncbi.nlm.nih.gov/articles/PMC12179442/
- LegiScan – S.545 Bill Status: https://legiscan.com/US/bill/SB545/2025
.
